A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Brolucizumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms MERLIN
- Sponsors Novartis Pharmaceuticals
- 22 Nov 2019 Planned End Date changed from 29 Sep 2020 to 14 Jan 2022.
- 11 Jul 2019 Planned End Date changed from 9 Jun 2020 to 29 Sep 2020.
- 10 Nov 2018 Planned End Date changed from 2 Jun 2020 to 9 Jun 2020.